UroGen Pharma (URGN) to Release Quarterly Earnings on Wednesday

UroGen Pharma (NASDAQ:URGN - Get Free Report) is scheduled to release its earnings data before the market opens on Wednesday, November 6th. Analysts expect UroGen Pharma to post earnings of ($0.84) per share for the quarter.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to analysts' expectations of $23.69 million. On average, analysts expect UroGen Pharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

UroGen Pharma Stock Down 4.8 %

UroGen Pharma stock traded down $0.62 during mid-day trading on Thursday, hitting $12.40. 259,540 shares of the company's stock were exchanged, compared to its average volume of 502,524. The company has a current ratio of 8.15, a quick ratio of 7.93 and a debt-to-equity ratio of 3.23. The stock has a market cap of $290.83 million, a P/E ratio of -3.74 and a beta of 1.11. UroGen Pharma has a 1-year low of $10.60 and a 1-year high of $20.70. The stock has a 50 day moving average of $13.03 and a two-hundred day moving average of $14.28.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Guggenheim began coverage on UroGen Pharma in a research report on Thursday, August 22nd. They issued a "buy" rating and a $40.00 price target on the stock. Oppenheimer reiterated an "outperform" rating and issued a $40.00 target price on shares of UroGen Pharma in a research note on Wednesday, October 16th. Finally, EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a "strong-buy" rating in a research note on Monday, October 14th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $48.38.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.